<DOC>
	<DOCNO>NCT02235259</DOCNO>
	<brief_summary>The objective study assess safety efficacy XG-104 Ophthalmic Solution compare placebo treatment sign symptom dry eye 4 week Three Times Day ( TID ) treatment period</brief_summary>
	<brief_title>Efficacy Safety XG-104 Treatment Dry Eye</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<criteria>Be least 18 year age Provide write informed consent Have subject report history dry eye Have history use desire use eye drop Have clinically significant eye finding require therapeutic treatment , and/or opinion Investigator may interfere study parameter ; Have wear contact lenses within 7 day Visit 1 anticipate use contact lens study ; Have previously laserassisted situ keratomileusis ( LASIK ) surgery within last 12 month ; Have use RestasisÂ® within 30 day Visit 1 ; Have plan ocular and/or lid surgery study period ; Be woman pregnant , nurse planning pregnancy ; Be unwilling submit urine pregnancy test Visit 1 Visit 4 ( early termination visit ) childbearing potential . Have know allergy and/or sensitivity study drug component Have condition situation Investigator feel may put subject significant risk , may confound study result , may interfere significantly subject 's participation study ; Be currently enrol investigational drug device study use investigational drug device within 30 day Visit 1 ; Be unable unwilling follow instruction , include participation study assessment visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>